← Back to patent-cliff list

MK-2206

Tier C — Watch / trade

MK-2206

MSD (Merck Sharp & Dohme)
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:AKT1

Indications (approved):Peritoneal cancer, Prostate cancer, Small cell lung cancer, 胸腺瘤, Non-small cell lung cancer, 皮肤黑色素瘤, Solid tumour, Renal cell carcinoma

Regional status

US
Phase II
2010-08-01
EU
Phase II
2011-03-17
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield /
MK-2206-00150921-39-6MK-2206-0021032349-96-4MK-2206-0031032349-97-5MK-2206-0041032349-98-6MK-2206-005893423-62-6MK-2206-0061032349-99-7MK-2206-0071032350-00-7MK-2206-0081032350-03-0API · MK-2206
CodeCAS No.Intermediate
MK-2206-00150921-39-61-(4-chlorophenyl)cyclobutane-1-carboxylic acid
MK-2206-0021032349-96-4tert-butyl (1-(4-chlorophenyl)cyclobutyl)carbamate
MK-2206-0031032349-97-5tert-butyl (1-(4-cyanophenyl)cyclobutyl)carbamate
MK-2206-0041032349-98-6tert-butyl (1-(4-(2-phenylacetyl)phenyl)cyclobutyl)carbamate
MK-2206-005893423-62-6tert-butyl (2-chloro-3-formylpyridin-4-yl)carbamate
MK-2206-0061032349-99-7tert-butyl (1-(4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl)cyclobutyl)carbamate
MK-2206-0071032350-00-7tert-butyl (1-(4-(5-hydrazineyl-3-phenyl-1,6-naphthyridin-2-yl)phenyl)cyclobutyl)carbamate
MK-2206-0081032350-03-0tert-butyl (1-(4-(3-hydroxy-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl)phenyl)cyclobutyl)carbamate

Frequently asked questions

What are the approved indications of MK-2206?

Approved indications include: Peritoneal cancer, Prostate cancer, Small cell lung cancer, 胸腺瘤, Non-small cell lung cancer, 皮肤黑色素瘤, Solid tumour, Renal cell carcinoma.

When does the MK-2206 patent expire?

No public expiry year is available for MK-2206 yet; this page updates once verified.

How many synthesis routes are recorded for MK-2206?

1 synthesis routes are recorded; the shortest is 7 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy MK-2206 intermediates?

All intermediates in MK-2206 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for MK-2206 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21